BACKGROUND: Local delivery of carmustine (BCNU) via biodegradable polymers has been shown to improve survival in patients with glioblastoma multiforme (GBM). In the current study, we hypothesized that local delivery of an anthracycline antibiotic, doxorubicin (DOX), might act to improve the survival of animals bearing experimental intracranial glioma. MATERIALS AND METHODS: Polyanhydride polymers (PCPP-SA), containing either 3% or 5% ADR by weight, were prepared using the mix-melt method. Forty male Fisher 344 rats received an intracranial challenge with a lethal dose of 9L gliosarcoma cells. Five days later, they received DOX or blank polymer. There were a total of four treatment groups: (1) blank polymer; (2) 3% DOX polymer; (3) 5% DOX polymer, and (4) control group with no polymer. RESULTS: Compared to control animals treated with no polymers or blank polymer, animals receiving DOX had significantly extended survival. The median survival for the control group was 21 days vs. 34 days (p < 0.01) for the 3% DOX group and 45 days (p < 0.0001) for the 5% DOX group. CONCLUSION: Doxorubicin, when delivered locally, is an effective monotherapeutic agent against experimental intracranial glioma.
BACKGROUND: Local delivery of carmustine (BCNU) via biodegradable polymers has been shown to improve survival in patients with glioblastoma multiforme (GBM). In the current study, we hypothesized that local delivery of an anthracycline antibiotic, doxorubicin (DOX), might act to improve the survival of animals bearing experimental intracranial glioma. MATERIALS AND METHODS:Polyanhydride polymers (PCPP-SA), containing either 3% or 5% ADR by weight, were prepared using the mix-melt method. Forty male Fisher 344 rats received an intracranial challenge with a lethal dose of 9L gliosarcoma cells. Five days later, they received DOX or blank polymer. There were a total of four treatment groups: (1) blank polymer; (2) 3% DOX polymer; (3) 5% DOX polymer, and (4) control group with no polymer. RESULTS: Compared to control animals treated with no polymers or blank polymer, animals receiving DOX had significantly extended survival. The median survival for the control group was 21 days vs. 34 days (p < 0.01) for the 3% DOX group and 45 days (p < 0.0001) for the 5% DOX group. CONCLUSION:Doxorubicin, when delivered locally, is an effective monotherapeutic agent against experimental intracranial glioma.
Authors: Ryuta Saito; John R Bringas; Tracy R McKnight; Michael F Wendland; Christoph Mamot; Daryl C Drummond; Dmitri B Kirpotin; John W Park; Mitchel S Berger; Krys S Bankiewicz Journal: Cancer Res Date: 2004-04-01 Impact factor: 12.701
Authors: Sebastian C J Steiniger; Jörg Kreuter; Alexander S Khalansky; Igor N Skidan; Alexey I Bobruskin; Zoya S Smirnova; Sergey E Severin; Reiner Uhl; Martin Kock; Kathrin D Geiger; Svetlana E Gelperina Journal: Int J Cancer Date: 2004-05-01 Impact factor: 7.396
Authors: Peter Hau; Klaus Fabel; Ulrike Baumgart; Petra Rümmele; Oliver Grauer; Annekatrin Bock; Christopher Dietmaier; Wolfgang Dietmaier; Jörg Dietrich; Christine Dudel; Franz Hübner; Tanya Jauch; Elisabeth Drechsel; Ingo Kleiter; Cäcile Wismeth; Anton Zellner; Alexander Brawanski; Andreas Steinbrecher; Jörg Marienhagen; Ulrich Bogdahn Journal: Cancer Date: 2004-03-15 Impact factor: 6.860
Authors: H Brem; M S Mahaley; N A Vick; K L Black; S C Schold; P C Burger; A H Friedman; I S Ciric; T W Eller; J W Cozzens Journal: J Neurosurg Date: 1991-03 Impact factor: 5.115
Authors: Byron C Masi; Betty M Tyler; Hansen Bow; Robert T Wicks; Yuan Xue; Henry Brem; Robert Langer; Michael J Cima Journal: Biomaterials Date: 2012-05-14 Impact factor: 12.479
Authors: Tânia Capelôa; Francisco Caramelo; Carlos Fontes-Ribeiro; Célia Gomes; Ana P Silva Journal: Neurotox Res Date: 2014-03-21 Impact factor: 3.911